A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

NCT05026905 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Phase II, Open-label, Parallel 2-arm, Multi-center

Interventions

DRUG: Gemcitabine 1000 mg
DRUG: Nab paclitaxel
DRUG: S1
DRUG: leucovorin
DRUG: Oxaliplatin

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]